[1] GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10513): 1811-1872.
[2] Lu K, Sui J, Yu W, et al. An analysis of the burden of liver cirrhosis: Differences between the global, China, the United States and India[J]. Liver Int, 2024, 44(12): 3183-3203.
[3] Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors[J]. Hepatology, 1987, 7(1): 122-128.
[4] Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006, 4(11): 1385-1394.
[5] D′Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231.
[6] Premkumar M, Kamath P S, Reiberger T, et al. Recompensation in decompensated cirrhosis[J]. Lancet Gastroenterol Hepatol, 2025, 10(11): 1028-1040.
[7] Reiberger T, Hofer B S. The Baveno Ⅶ concept of cirrhosis recompensation[J]. Dig Liver Dis, 2023, 55(4): 431-441.
[8] 王亚萍 杨秀涵, 蔡海奕. 肝硬化再代偿不同分期的临床研究进展[J]. 中华肝脏病杂志, 2025, 33(08): 715-720.
[9] D′Amico G, Morabito A, D′Amico M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis[J]. Hepatol Int, 2018, 12(Suppl 1): 34-43.
[10] D′Amico G, Morabito A, D′Amico M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3): 563-576.
[11] Pugh R N, Murray-Lyon I M, Dawson J L, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649.
[12] Malinchoc M, Kamath P S, Gordon F D, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871.
[13] Verma N, Kaur P, Garg P, et al. Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis[J]. J Hepatol, 2025, 83(3): 670-681.
[14] Miyata T, Wu X, Fan X, et al. Differential role of MLKL in alcohol-associated and non-alcohol-associated fatty liver diseases in mice and humans[J]. JCI Insight, 2021, 6(4): e140180.
[15] Liang J, Han T, Gao Y T, et al. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease[J]. Eur Rev Med Pharmacol Sci, 2015, 19(21): 4123-4129.
[16] Arvaniti V, D′Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256, 1256.e1-5.
[17] Vucur M, Roderburg C, Kaiser L, et al. Elevated serum levels of mixed lineage kinase domain-like protein predict survival of patients during intensive care unit treatment[J]. Dis Markers, 2018, 1983421. |
